ProFibrix Completes Enrollment of Phase II Studies with Lead Hemostasis Product FibrocapsTM and Targets Start of Phase III in H1 2012

Published: Sep 13, 2011

LEIDEN, The Netherlands & SEATTLE--(BUSINESS WIRE)--ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II studies with lead product Fibrocaps in surgical hemostasis.

Back to news